Aurora Innovation, Inc. logo

Aurora Innovation, Inc. (AUR)

Market Closed
14 Aug, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
6. 99
+0.15
+2.193%
$
13.71B Market Cap
- P/E Ratio
- Div Yield
16.55M Volume
- Eps
$ 6.84
Previous Close
Add Transaction
Day Range
6.68 7.1
Year Range
3.6 8.56
Want to track AUR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Ncc Group (OTCMKTS:NCCGF) & Aurora Innovation (NASDAQ:AUR) Financial Review

Ncc Group (OTCMKTS:NCCGF) & Aurora Innovation (NASDAQ:AUR) Financial Review

Ncc Group (OTCMKTS:NCCGF - Get Free Report) and Aurora Innovation (NASDAQ: AUR - Get Free Report) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Analyst Recommendations This is a summary of

Defenseworld | 5 months ago
Aurora Innovation, Inc. (AUR) Presents at 2nd Annual CG virtual Sustainability Summit Transcript

Aurora Innovation, Inc. (AUR) Presents at 2nd Annual CG virtual Sustainability Summit Transcript

Aurora Innovation, Inc. (AUR) Presents at 2nd Annual CG virtual Sustainability Summit Transcript

Seekingalpha | 5 months ago
Aurora Innovation, Inc. (AUR) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

Aurora Innovation, Inc. (AUR) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

Aurora Innovation, Inc. (AUR) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript

Seekingalpha | 5 months ago
Aurora Innovation: Too Slow To Commercialize

Aurora Innovation: Too Slow To Commercialize

Aurora Innovation: Too Slow To Commercialize

Seekingalpha | 5 months ago
Aurora Innovation, Inc. (AUR) Q4 2025 Earnings Call Transcript

Aurora Innovation, Inc. (AUR) Q4 2025 Earnings Call Transcript

Aurora Innovation, Inc. (AUR) Q4 2025 Earnings Call Transcript

Seekingalpha | 6 months ago
Aurora Innovation, Inc. (AUR) Reports Q4 Loss, Misses Revenue Estimates

Aurora Innovation, Inc. (AUR) Reports Q4 Loss, Misses Revenue Estimates

Aurora Innovation, Inc. (AUR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.11 per share a year ago.

Zacks | 6 months ago
Aurora Innovation: Scaling Up Will Be The New Test (Rating Upgrade)

Aurora Innovation: Scaling Up Will Be The New Test (Rating Upgrade)

Aurora (AUR) is upgraded to Buy with a $5.8 price target, reflecting 22% upside amid early commercialization momentum. AUR has robust $1.25B liquidity, and a narrowing net loss, supporting a 15+ month runway. Key 2026 catalysts include second-generation hardware (50% cost reduction) and the Detmar Logistics contract, validating scalability and technology maturity.

Seekingalpha | 7 months ago
Aurora Innovation: 2026 Still Isn't The Year Of Autonomous Trucking

Aurora Innovation: 2026 Still Isn't The Year Of Autonomous Trucking

Aurora Innovation remains in a cautious crawl phase, with limited near-term revenue and slow scaling despite initial autonomous trucking lane launches. The autonomous trucking company targets only several hundred driverless trucks by end of 2026, while competitors like Kodiak AI and PlusAI are accelerating, eroding any first-mover advantage. Financials are challenging: $1M quarterly revenue, $9B market cap, significant cash burn, and ongoing share dilution to fund operations.

Seekingalpha | 7 months ago
Will Aurora Innovation (AUR) Stock Explode to $10?

Will Aurora Innovation (AUR) Stock Explode to $10?

If the roadways are filled with self-driving trucks someday, then Aurora Innovation (NASDAQ:AUR) and its investors could be due for a financial windfall.

247wallst | 9 months ago
Aurora Innovation, Inc. (AUR) Reports Q3 Loss, Lags Revenue Estimates

Aurora Innovation, Inc. (AUR) Reports Q3 Loss, Lags Revenue Estimates

Aurora Innovation, Inc. (AUR) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.13 per share a year ago.

Zacks | 9 months ago
Aurinia Pharmaceuticals: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating

Aurinia Pharmaceuticals: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating

Aurinia Pharmaceuticals is rated BUY, driven by strong Lupkynis sales growth and a robust cash position supporting pipeline development. AUPH's Lupkynis leads as the first FDA-approved oral therapy for lupus nephritis, with 22% YoY revenue growth and expanding physician adoption. The company's pipeline drug, AUR200, targets dual immune proteins and offers long-term diversification potential in a multi-billion-dollar autoimmune market.

Seekingalpha | 9 months ago
Aurora Innovation, Inc. (AUR) Presents at Evercore ISI's Autonomous, ADAS & AI Forum Transcript

Aurora Innovation, Inc. (AUR) Presents at Evercore ISI's Autonomous, ADAS & AI Forum Transcript

Aurora Innovation, Inc. (NASDAQ:AUR ) Evercore ISI's Autonomous, ADAS & AI Forum September 30, 2025 10:15 AM EDT Company Participants David Maday - Chief Financial Officer Conference Call Participants Chris McNally - Evercore ISI Institutional Equities, Research Division Presentation Chris McNally Evercore ISI Institutional Equities, Research Division Thanks so much for coming back. Chris McNally, Evercore ISI.

Seekingalpha | 10 months ago
Loading...
Load More